Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 3, 2010, Pages 268-277

  Rungrotmongkol, Thanyada ^a,b   Udommaneethanakit, Thanyarat ^a,b   Frecer, Vladimir ^a,c,d   Miertus, Stanislav ^a  

^a UNIDO   (Italy)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c AREA Science Park   (Italy)

^d CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Avian influenza virus H5N1; Computerassisted combinatorial library design; In silico screening; Neuraminidase inhibitors; Pyrrolidine based analogs; Target specific scoring function; Viral drug resistance

Indexed keywords

A 315675; A 322278; OSELTAMIVIR; PERAMIVIR; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER SIMULATION; DRUG DESIGN; ENZYME INHIBITORS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; MODELS, MOLECULAR; NEURAMINIDASE; PYRROLIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

AVES; AVIAN INFLUENZA VIRUS;

EID: 77949855256     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710790980504     Document Type: Article

References (41)

1. Gubareva, L.V.; Kaiser, L.; Hayden, F.G. Influenza virus neuraminidase inhibitors. Lancet., 2000, 355, 827-835.
2. Bantia, S.; Arnold, C.S.; Parker, C.D.; Upshaw, R.; Chand, P. Antiinfluenza virus activity of peramivir in mice with single intramuscular injection. Antivir. Res., 2006, 69, 39-45.
3. Lackenby, A.; Thompson, C.I.; Democratis, J. The potential impact of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis., 2008, 21, 626-638.
4. Gubareva, L.V.; Kaiser, L.; Matrosovich, M.N.; Soo-Hoo, Y.; Hayden, F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis., 2001, 183, 523-531.
5. Moscona, A. Oseltamivir resistance--disabling our influenza defenses. N. Engl. J. Med., 2005, 353, 2633-2636.
6. Collins, P.J.; Haire, L.F.; Lin, Y.P.; Liu, J.; Russell, R.J.; Walker, P.A.; Skehel, J.; Martin, S.R.; Hay, A.J.; Gamblin, S.J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature, 2008, 453, 1258-1261.
7. DeGoey, D.A.; Chen, H.J.; Flosi, W.J.; Grampovnik, D.J.; Yeung, C.M.; Klein, L.L.; Kempf, D.J. Enantioselective synthesis of antiinfluenza compound A-315675. J. Org. Chem., 2002, 67, 5445-5453.
8. Kati, W.M.; Montgomery, D.; Carrick, R.; Gubareva, L.; Maring, C.; McDaniel, K.; Steffy, K.; Molla, A.; Hayden, F.; Kempf, D.; Kohlbrenner, W. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother., 2002, 46, 1014-1021.
9. Abed, Y.; Nehmé, B.; Baz, M.; Boivin, G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antivir. Res., 2008, 77, 163-166.
10. Warr, W.A. Combinatorial chemistry and molecular diversity. An overview. J. Chem. Inf. Comput. Sci., 1997, 37, 134-140.
11. Kubinyi, H. Combinatorial and computational approaches in structurebased drug design. Curr. Opin. Drug Disc. Dev., 1998, 1, 16-27.
12. Frecer, V.; Kabelac, M.; De Nardi, P.; Pricl, S.; Miertus, S. Structurebased design of inhibitors of NS3 serine protease of hepatitis C virus. J. Mol. Graph. Model., 2004, 22, 209-220.
13. Frecer, V.; Burello, E.; Miertus, S. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1. Bioorg. Med. Chem., 2005, 13, 5492-5501.
14. Frecer, V.; Megnassan, E.; Miertus, S. Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase. Eur. J. Med. Chem., 2009, 44, 3009-3019.
15. Malaisree, M.; Rungrotmongkol, T.; Decha, P.; Intharathep, P.; Aruksakunwong, O.; Hannongbua, S. Understanding of known drugtarget interactions in the catalytic pocket of neuraminidase subtype N1. Proteins, 2008, 71, 1908-1918.
16. Malaisree, M.; Rungrotmongkol, T.; Nunthaboot, N.; Aruksakunwong, O.; Intharathep, P.; Decha, P.; Sompornpisut, P.; Hannongbua, S. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. Amino Acids, 2009, 725-732.
17. Rungrotmongkol, T.; Frecer, V.; De-Eknamkul, W.; Hannongbua, S.; Miertus, S. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Antivir. Res., 2009, 82, 51-58.
18. Krueger, A.C.; Xu, Y.; Kati, W.M.; Kempf, D.J.; Maring, C.J.; McDaniel, K.F.; Molla, A.; Montgomery, D.; Kohlbrenner, W.E. Synthesis of potent pyrrolidine influenza neuraminidase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 1692-1695.
19. Russell, R.J.; Haire, L.F.; Stevens, D.J.; Collins, P.J.; Lin, Y.P.; Blackburn, G.M.; Hay, A.J.; Gamblin, S.J.; Skehel, J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature, 2006, 443, 45-49.
20. AMBER Archive, version 10. San Francisco: University of California 2002.
21. Li, H.; Robertson, A.D.; Jensen, J.H. Very fast empirical prediction and rationalization of protein pKa values. Proteins, 2005, 61, 704-721.
22. Gaussian 03, Revision C. 02. Wallingford, CT: Gaussian, 2004.
23. Wang, J.M.; Wang, W.; Kollman, P.A. Antechamber: an accessory software package for molecular mechanical calculations. J. Am. Chem. Soc., 2001, 222, U403-U403.
24. Cornell, W.D.; Cieplak, P.; Bayly, C.I.; Gould, I.R.; Merz, K.M.; Ferguson, D.M.; Spellmeyer, D.C.; Fox, T.; Caldwell, J.W.; Kollman, P.A. A Second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc., 1995, 117, 5179-5197.
25. Cerius2 Life Sciences, version 4.5, Accelrys, San Diego, CA, 2000.
26. Maple, J.R.; Hwang, M.J.; Stockfish, T.P.; Dinur, U.; Waldman, M.; Ewing, C.S.; Hagler, A.T. Derivation of class II force fields. I. Methodology and quantum force field for the alkyl functional group and alkane molecules. J. Comput. Chem., 1994, 15, 162-182.
27. Rappé, A.K.; Goddard, W.A. Charge equilibration for molecular dynamics simulations. J. Phys. Chem., 1991, 95, 3358-3363.
28. ChemBioFinder.Com, Scientific Database Gateway, version 2.0.0.26
29. Willett, P. In: Molecular Similarity in Drug Design; P. M. Dean, Ed.; Chapman and Hall: Glasgow, 1994, pp. 110-137.
30. Peters, K.P.; Fauck, J.; Frömmel, C. The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. J. Mol. Biol., 1996, 256, 201-213.
31. Muegge, I.; Martin, Y.C. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem., 1999, 42, 791-804.
32. Muegge, I. Effect of ligand volume correction on PMF scoring. J. Comp. Chem., 2001, 22, 418-425.
33. Verkhivker, G.; Appelt, K.; Freer, S.T.; Villafranca, J.E. Empirical free energy calculations of ligand-protein crystallographic complexes. I. Knowledge-based ligand-protein interaction potentials applied to the prediction of human immunodeficiency virus 1 protease binding affinity. Protein Eng., 1995, 8, 677-691.
34. Verkhivker, G.M.; Bouzida, D.; Gehlhaar, D.K.; Rejto, P.A.; Arthurs, S.; Colson, A.B.; Larson, V.; Luty, B.A.; Marrone, T.; Rose, P.W. Deciphering common failures in molecular docking of ligand-protein complexes. J. Comp. Aided Mol. Des., 2000, 14, 731-751.
35. Böhm, H.J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comp. Aided Mol. Des., 1994, 8, 243-256.
36. Böhm, H.J. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J. Comp. Aided Mol. Des.,1998, 12, 309-323.
37. QikProp, version 2.0.005, Schrödinger, Inc., New York, NY, 2002.
38. Duffy, E.M.; Jorgensen, W.L. Prediction of properties from simulations: Free energies of solvation in hexadecane, octanol, and water. J. Am. Chem. Soc., 2000, 122, 2878-2888.
39. Jorgensen, W.L.; Duffy, E.M. Prediction of drug solubility from Monte Carlo simulations. Bioorg. Med. Chem. Lett., 2000, 10, 1155-1158.
40. Jorgensen W.L.; Duffy E.M. Prediction of drug solubility from structure. Adv. Drug Deliv. Rev., 2002, 54, 355-366.
41. Hurt, A.C.; Selleck, P.; Komadina, N.; Shaw, R.; Brown, L.; Barr, I.G. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res., 2007, 73, 228-231.